时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Nature Aging Statinspromoteboneanabolism inestrogendeficiencybyinducing osteogenicdifferentiationofskeletal stem/progenitorcells Min Yang1,2,3,12 , Jiaming Guo2,3,4,12 , Juan Ye5,12 , Xiangjiao Meng2,3,6 , Yunran Ma2,3,7 , Yuehan Ni1,2,3 , Tingyi Chen2,3,7 , Yixuan Zhang2,3,4 , Hanyao Guo2,3 , Ge Shen2,3,4 , Yi Yuan8 , Xinyi Qiao8 , Yifei Wu9 , Jiaojiao Li2,3 , Xiangbing Qi2,3 , Shentong Fang10 , Ling Wang 8,11,13 & Bo Shen 2,3,13 Menopause-associatedestrogendeficiencydrivesage-relatedbonelossin women.Statinusehasbeenassociatedwithhigherbonemineraldensityin postmenopausalwomen,butwhethermenopausealtersskeletalresponses tostatinsremainsunclear.Here,weshowthatstatinusewasassociated withaslowerannualdeclineinbonemineraldensityinpostmenopausal womenandthatatorvastatinpromotesboneanabolismspecificallyunder estrogen-deficientconditionsbyinducingosteogenicdifferentiation ofleptinreceptor-expres
方法
Although hormone replacement therapy is the principal treatment to counteract these effects, its use is limited by eligibility criteria, timing and risk factors, leaving many women untreated or intermittently treated2,3 .；Observational studies have reported that statin use is associated with higher bone mineral density (BMD)4 or reduced fracture risk in postmenopausal women5 andolderpopulations6,7 ,althoughresultshavevariedacrosscohorts, endpoints and study designs5–8 .；By integrating two postmenopausal clinical cohorts with stud- ies of aged female and ovariectomized mice, we found that statin use was associated with a slower annual decline in BMD and that atorvastatin promoted bone anabolism under estrogen-deficient conditions.；To evaluate the impact of statins on bone in estrogen-deficient women, we performed a retrospective analysis of paired dual-energy X-rayabsorptiometry(DXA)dataf
核心结论
Nature Aging Statinspromoteboneanabolism inestrogendeficiencybyinducing osteogenicdifferentiationofskeletal stem/progenitorcells Min Yang1,2,3,12 , Jiaming Guo2,3,4,12 , Juan Ye5,12 , Xiangjiao Meng2,3,6 , Yunran Ma2,3,7 , Yuehan Ni1,2,3 , Tingyi Chen2,3,7 , Yixuan Zhang2,3,4 , Hanyao Guo2,3 , Ge Shen2,3,4 , Yi Yuan8 , Xinyi Qiao8 , Yifei Wu9 , Jiaojiao Li2,3 , Xiangbing Qi2,3 , Shentong Fang10 , Ling Wang 8,11,13 & Bo Shen 2,3,13 Menopause-associatedestrogendeficiencydrivesage-relatedbonelossin women.Statinusehasbeenassociatedwithhigherbonemineraldensityin postmenopausalwomen,butwhethermenopausealtersskeletalresponses tostatinsremainsunclear.Here,weshowthatstatinusewasassociated withaslowerannualdeclineinbonemineraldensityinpostmenopausal womenandthatatorvastatinpromotesboneanabolismspecificallyunder estrogen-deficientconditionsbyinducingosteogenicdifferentiation ofleptinreceptor-expressing(LEPR+ )bonemarrowstromalcells,which includeskeletalstem/progenitorcells.Atorvastatinincreasesosteoblast formationbyrestrictingRAC1prenylationandenablingnuclearfactor kappaB-mediatedOlntranscripti ‖ 结论：Age at menopause, years since menopause and the interval between paired DXA scans were obtained from clinical records and are reported together with other baseline variables in ExtendedDataFig.1a,b.Participantswerestratifiedintothreegroups based on pharmacy dispensing and administration records: (i) statin users, defined as individuals who received continuous statin therapy throughout the interval between the paired DXA scans used to com- pute annualized BMD change; (ii) evolocumab users, defined as indi- viduals who received subcutaneous evolocumab, a PCSK9 inhibitor, throughouttheintervalbet
局限
Observational studies have reported that statin use is associated with higher bone mineral density (BMD)4 or reduced fracture risk in postmenopausal women5 andolderpopulations6,7 ,althoughresultshavevariedacrosscohorts, endpoints and study designs5–8 .；Totestthisdirectly,wegeneratedadoxycycline-inducibleTet-On Lepr-Cre allele to examine the osteogenic fate of LEPR+ cells in vivo whileavoidingpotentialconfoundingeffectsoftamoxifen,anestrogen receptor modulator with well-documented bone anabolic activity21 .；Statins inhibit 3-hydroxy- 3-methyl-glutaryl-CoAreductase,therate-limitingenzymeofthispath- way, reducing the production of isoprenoid intermediates required for non-sterol metabolic proce
对本项目的价值
★★☆☆☆ 衰弱/肌少症是少有的已有监管认可终点的老年综合征，是临床转化的最短路径。
全文来源
出版商 OA PDF（正文 110,007 字符，已过 DOI 逐字 / 标题指纹归属校验）
原文题录
- 英文标题：Statins promote bone anabolism in estrogen deficiency by inducing osteogenic differentiation of skeletal stem/progenitor cells.
- 期刊与标识：Nat Aging · PMID 42946859 · DOI 10.1038/s43587-026-01257-1
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。